LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microbiota’s Role Explored in Colorectal Cancer Among the Young

By LabMedica International staff writers
Posted on 06 Feb 2020
Print article
Image: Photomicrograph of the bacterium, Fusobacterium nucleatum:  gram-negative stained from culture (Photo courtesy of J. Michael Miller, PhD, (D)ABMM)
Image: Photomicrograph of the bacterium, Fusobacterium nucleatum: gram-negative stained from culture (Photo courtesy of J. Michael Miller, PhD, (D)ABMM)
Colorectal cancer incidence has been declining for several decades in people over 55, in part because of the increased use of screening for the disease, particularly with colonoscopy which can find and remove polyps before they become cancerous.

However such screenings are generally not recommended for people under age 50, but colorectal cancer rates have been increasing at nearly a 2% annual rate in people under age 55 since 2006. There are many theories about why, including a rise in obesity, diabetes, and diets low in whole grains among younger people.

Bacteria typically linked to periodontal disease, Fusobacterium nucleatum, could play an important role in the rising incidence of colorectal cancer in people under the age of 45. Another type of bacteria, Moraxella osloensis, has been found in colorectal cancer tumors at a nearly four-fold higher rate in people over 75 than in those under 45 years of age, pointing out how differences in the bacteria that comprise what is known as the body's microbiome could affect cancer outcomes to varying degrees.

Oncologists at the Georgetown Lombardi Comprehensive Cancer Center (Washington, DC, USA) analyzed the role of the microbiome in colorectal cancer. To do this they looked at the DNA and microbiome of archived tumors, as well as adjacent normal tissue when available, from 31 patients with colorectal cancer who were diagnosed before the age of 45 or after the age of 65.

Scientists have known that certain microbes that comprise the microbiome, which consists of different types of bacteria, fungi and viruses, can disturb the lining of the colon and promote tissue inflammation. This can result in mutations to the DNA of cells in the colon and lead to cancer. Scientists also know that F. nucleatum can promote cancerous growth by suppressing immune responses in the colon.

Overall, the investigators found 478 unique bacterial and fungal species in the tumors. One of the most common bacteria found was F. nucleatum, which appeared in five of the younger patients' tumors and in three of the older patients' tumors. The team also found a significant difference in the rate of Moraxella osloensis (11% versus 46%) in younger compared to older patients.

Benjamin Adam Weinberg, MD, an assistant professor of medicine and a senior author of the study, said, “There was a much higher presence of F. nucleatum in younger patients than we expected. We haven't seen large genetic differences in colorectal tumors from younger versus older people, so we hypothesize that something else, perhaps the microbiome, is contributing to the rise in incidence of the disease in younger people.” The study was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium held January 23-25, 2020 in San Francisco, CA, USA).

Related Links:
Georgetown Lombardi Comprehensive Cancer Center

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.